Companies › Shanghai YingLi Pharmaceutical
1 active drug program in 1 registered trial: 1 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| YL-17231 Pan-RAS inhibitor | KRAS, HRAS, NRAS | Phase 1 | Advanced Solid Tumors | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06096974 | YL-17231 | Phase 1 | Advanced Solid Tumors | Oncology | Oct 2025 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.